Abstract

Background: Urinary tract infections (UTIs) are the third most common type of infection in humans globally. Gram-positive bacteria are said to be responsible for ten percent of urinary tract (UTI) infections. The study's goal was to profile gram-positive cocci-associated UTIs and their antibiogram, as they were observed at LASUTH. Methods: This was a retrospective assessment of the Medical Microbiology Laboratory records of the LASUTH to review the in vitro antibiotic susceptibility patterns of gram-positive urinary bacterial isolates between April 2020 and March 2021. The bacteria were isolated and identified from routine urine samples using standard bacteriological methods and the API. In vitro antibiotic susceptibility test (AST) was routinely performed by the modified Kirby-Bauer disk diffusion test and susceptibility breakpoints were determined using the Clinical and Laboratory Standards Institute (CLSI) guidelines. Results: 2,253 urine samples were processed in the medical microbiology laboratory over the one year and 662 (29.4%) samples yielded Positive cultures. Of the 662 isolates, 494 (74.6%) were gram-negative bacteria. 164 (24.8%) were gram-positive cocci while 4 (0.6%) were gram positive rod. Among the gram-positive cocci’s isolated Enterococcus faecalis had the highest frequency 58 (35.4%). Aminoglycosides (Gentamycin and Amikacin) and Linezolid antibiotics were found to be the most effective drugs against gram-positive cocci bacteria except Enterococcus spp. For empirical treatment of Enterococcus spp in our facility Fosfomycin and Tigecycline are the best options, while for Streptococcus agalactiae associated UTI, Amikacin, Cefuroxime, Linezolid, and levofloxacin can be used for empirical treatment. Conclusion: The prevalence rate of gram-positive cocci associated UTI in this study was 7.3% (164/2253). The emergence of drug resistance in these pathogens to commonly used antibiotics is a thing of concern. Therefore, efficient antimicrobial stewardship programmes must be in place.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.